ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Protalix Reaches Deal With Brazil

by Marc S. Reisch
July 1, 2013 | APPEARED IN VOLUME 91, ISSUE 26

Protalix BioTherapeutics will transfer the technology for its enzyme replacement therapy to treat Gaucher’s disease, a rare lysosomal storage disorder, to an arm of Brazil’s Ministry of Health. The agreement calls for Protalix to transfer the skills required to make alfataliglicerase for Brazilian patients to Fundação Oswaldo Cruz (Fiocruz) over the next seven years. While Fiocruz constructs a facility, it will purchase at least $280 million of the enzyme from Protalix. Pfizer, which distributes the drug, will receive more than $12 million per year from Protalix during the agreement.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment